The Problematic Lag between FDA Approval of Medical Devices and CMS
Coverage
- Bradley Knight
, - Thomas Deering,
- Michael Gold,
- Suneet Mittal,
- Jagmeet Singh
Thomas Deering
Piedmont Heart Institute Arrhythmia Center
Author ProfileAbstract
Significant changes or cancellation of MCIT could result in limiting
access to breakthrough medical technologies that could improve the
health and well-being of Medicare beneficiaries. For these reasons, we
encourage federal agencies to work together and CMS to implement the
MCIT rule without delay to ensure timely access to breakthrough
technologies21 Apr 2021Submitted to Journal of Cardiovascular Electrophysiology 21 Apr 2021Submission Checks Completed
21 Apr 2021Assigned to Editor
21 Apr 2021Review(s) Completed, Editorial Evaluation Pending
21 Apr 2021Editorial Decision: Accept
